The consequent suggestion is to focus instead on human neural cell-based preclinical brain diseases models, which could drive etiological, pathogenetic, and therapeutic advances, including proper NLRP3 and other inflammasome regulation, and minimize failure risks concerning lead candidate drug testing in clinical trials. Here, NLRP3 is linked to brain disorder.